T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

DISEASE CHARACTERISTICS: * Diagnosis of 1 of the following hematologic malignancies: * Acute myeloid leukemia (AML), meeting 1 of the following criteria: * In first complete remission (CR1), meeting 1 of the following criteria: * Adverse cytogenetics with minimal residual disease detectable by flow cytometry, cytogenetic analysis, fluorescence in situ hybridization (FISH), or polymerase chain reaction (PCR), defined as 1 of the following: * Complex karyotype \[≥ 3 abnormalities\] * inv(3) or t(3;3) * t(6;9) * t(6;11) * Monosomy 7 * Trisomy 8, alone or with an abnormality other than t(8;21), t(9;11), inv(16), or t(16;16) * t(11;19) (q23;p13.1) * Failed to achieve CR after primary induction chemotherapy * Secondary AML * In second or subsequent remission (CR2 or greater) * Acute lymphoblastic leukemia, meeting 1 of the following criteria: * In CR1, meeting 1 of the following criteria: * Adverse cytogenetics with minimal residual disease detectable by flow cytometry, cytogenetic analysis, FISH, or PCR, defined as the following: * Translocations involving 11q23, t(9;22), or bcr-abl rearrangement * Failed to achieve CR after primary induction chemotherapy * In CR2, if CR1 was \< 12 months * In CR3 or greater * Myelodysplastic syndromes (MDS) * INT-2 or high-risk by International Prognostic Scoring System * No MDS with Fanconi anemia * Chronic m…